The expression levels of B7-H4 have been reported to be associated with immunosuppression in the tumor microenvironment, tumor progression and poor prognosis, including urinary tract urothelial carcinoma, cervical cancer, colorectal cancer, lung cancer, ovarian cancer and breast cancer [16, 26, 36–39]. Here, VTCN1 is linked to ovarian carcinoma.